Abstract
Background and Aim: Hepatitis delta virus (HDV) infection is among the most aggressive forms of chronic viral hepatitis: fibrosis advances quickly, and cirrhosis, hepatocellular carcinoma (HCC) and hepatic decompensation develop more often than with other hepatitis viruses. Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading chronic liver disorder worldwide, and it may add to liver damage when it occurs alongside viral hepatitis. To date, however, data on MASLD in patients with chronic HDV infection remain scarce. We therefore aimed to describe the frequency of MASLD, assessed by transient elastography (FibroScan), in patients with chronic HDV infection and to examine whether it was associated with the severity of liver fibrosis. Methods: A total of 125 anti-HDV seropositive patients were enrolled in this cross-sectional study between March and September 2024. HDV-RNA was tested in all participants. FibroScan provided liver stiffness measurement (LSM, kPa) and the controlled attenuation parameter (CAP, dB/m). We used CAP ≥248 dB/m to identify steatosis and LSM ≥12.5 kPa to identify cirrhosis. Because cardiometabolic risk factors were not systematically recorded, MASLD was defined operationally by CAP. Multivariable logistic regression was used to look for factors linked to advanced fibrosis (LSM ≥9.5 kPa). Results: The mean age was 39.0 years, and 74.4% (n=93) of patients were male. HDV-RNA was detectable in 68.0% (n=85). Of the 85 patients previously treated with pegylated interferon-alpha, 26 (30.6%) had a sustained virological response (SVR). The cohort had a mean LSM of 10.6 kPa and a mean CAP of 232.1 dB/m; cirrhosis was present in 15.2% (n=19). MASLD was found in 24.0% (n=30), and 20.0% (n=25) had steatosis together with LSM ≥7.0 kPa. Patients with and without MASLD were similar in age, sex, HDV-RNA status, liver stiffness, cirrhosis rate and SVR rate (36.4% vs. 28.6%, p=0.593). After adjustment, detectable HDV-RNA remained linked to advanced fibrosis (adjusted odds ratio [aOR] 4.89, 95% CI 2.13–11.26, p<0.001), whereas MASLD was not (aOR 0.82, 95% CI 0.32–2.12, p=0.684). Conclusion: About one in four patients with chronic HDV infection had hepatic steatosis, so viral and metabolic liver injury frequently coexist in this group. Fibrosis severity, however, was related to ongoing HDV replication rather than to steatosis. Whether this dual burden affects long-term outcomes warrants prospective evaluation.

This publication has 27 references indexed in Scilit: